A Phase 2B Double-Blind Randomized Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Systemic Lupus Erythematosus
  • Age: Between 18 - 75 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants who are willing and able to comply with all the study procedures.
    2. Have a clinical diagnosis of SLE
    3. Have serologically positive SLE
    4. Currently receiving a stable dose of/or have documented failed therapy with one of the following: methotrexate (MTX), azathioprine (AZA), mycophenolate/mycophenolic acid (MMF), anti-malarials (hydroxychloroquine or chloroquine) or corticosteroids (if monotherapy, greater than or equal to 7.5 mg per day)
    5. Have active disease defined as:
      • SLEDAI-2K score of =6 points at screening, and “Clinical” SLEDAI-2K score of =4 points at both screening and randomization
      • BILAG Level A disease in =1 organ system
    6. Participants weighing greater than 35 kg and less than 130 kg
    7. Capable of giving signed informed consent

You may not be eligible for this study if the following are true:

    1. Have active renal lupus
    2. Have severe active central nervous system (CNS) lupus
    3. Have cancer or a history of cancer within 5 years of screening
    4. Have a history of a major organ transplant
    5. Have a history of thrombosis
    6. Have acute coronary syndrome
    7. Have pre-existing demyelinating disorder
    8. A history of additional risk factors for torsade de pointes
    9. A participant with any condition possibly affecting oral drug absorption
    10. Have a history of lymphoproliferative disease
    11. 1. Have active fibromyalgia/myofascial/chronic pain that, in the investigator’s opinion, would make it difficult to appropriately assess SLE activity for the purposes of this study
    12. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.